ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 6 of 390 for:    "Muscular Dystrophies"

Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02704325
Recruitment Status : Withdrawn
First Posted : March 10, 2016
Last Update Posted : February 6, 2018
Sponsor:
Information provided by (Responsible Party):
Kevin Flanigan, Nationwide Children's Hospital

Brief Summary:
The proposed clinical trial study of rAAVrh74.MCK.GALGT2 for duchenne muscular dystrophy (DMD) patients that will involve direct intramuscular injection to the extensor digitorum brevis muscle (EDB).

Condition or disease Intervention/treatment Phase
Duchenne Muscular Dystrophy Biological: rAAVrh74.MCK.GALGT2 Other: PLACEBO (Saline) Phase 1 Phase 2

Detailed Description:
This is a phase I safety and tolerability study. Three DMD subjects will receive bilateral injections into the EDB muscle, with one EDB receiving the GALGT2 vector (rAAVrh74.MCK.GALGT2) and the other side receiving saline alone (assigned in a randomized fashion). Three subjects will receive a single gene transfer dose of 1E12 vector genomes, and patients and investigators will be blinded as to which muscle is injected with vector. Muscle biopsies will be performed at three months (12 weeks) in two subjects and at 1.5 months (6 weeks) in one subject and evaluated blindly for the expression of the GALGT2 transgene.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: This is a dose escalation trial that will begin with the minimal efficacious dose as determined by preclinical studies and approved by the FDA. During the course of the trial, if safety is shown the dose will be escalated according to the clinical protocol.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2
Estimated Study Start Date : April 2016
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : February 2020


Arm Intervention/treatment
Experimental: GALGT2 Viral Vector
Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
Biological: rAAVrh74.MCK.GALGT2
Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.

Experimental: Saline
Dose: 1E12 vg (total dose) (n=3) of rAAVrh74.MCK.GALGT2 vs Placebo (Saline). All participants will receive rAAVrh74.MCK.GALGT2 in the right or the left EDB muscle and receive Saline in the opposite EDB muscles. The investigator will not know which side will receive rAAVrh74.MCK.GALGT2 vs Saline until after the trial is over. At the end of the trial the investigator will be unblinded.
Other: PLACEBO (Saline)
Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.




Primary Outcome Measures :
  1. Treatment related toxicities [ Time Frame: 2 years ]
    Based on the development of unacceptable toxicity defined as the occurrence of any one Grade III or higher treatment-related toxicities.


Secondary Outcome Measures :
  1. Expression of GALGT2 demonstrated with anti-CT epitope antibodies. [ Time Frame: 6 or 12 weeks ]
  2. GALGT2 protein expression quantified by western blot and assessed by densitometry [ Time Frame: 6 or 12 weeks ]
  3. Transduction efficiency measured by qPCR of the GALGT transgene from muscle, and expressed as vector genomes normalized to a genomic single-copy control. [ Time Frame: 6 or 12 weeks ]
  4. Number of fibers containing central nuclei compared between muscles by paired t-tests [ Time Frame: 6 or 12 weeks ]
  5. Dystrophin expression demonstrated with antibodies to N-terminal, C-terminal, and rod domains [ Time Frame: 6 or 12 weeks ]
  6. Utrophin expression [ Time Frame: 6 or 12 weeks ]
  7. Leukocyte markers including CD45, CD3, CD4, CD8, and MAC 387 [ Time Frame: 6 or 12 weeks ]
  8. Muscle will be examined for histological appearance [ Time Frame: 6 or 12 weeks ]
  9. Antibodies to rAAVrh74 along with PBMC ELISpots to both rAAVrh74 capsid and GALGT protein will be evaluated at different time points during the study [ Time Frame: 6 or 12 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   9 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Nonambulant subjects, age 9 or older
  • Confirmed mutation in the DMD gene using a clinically accepted technique that completely defines the mutation
  • A magnetic resonance image of the EDB showing preservation of sufficient muscle mass to permit transfection
  • Males of any ethnic group will be eligible
  • Ability to cooperate with all study procedures
  • Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (If appropriate).
  • Stable dose of corticosteroid therapy (including either prednisone or deflazacort and their generic forms) for 12 weeks prior to gene transfer

Exclusion Criteria:

  • Active viral infection based on clinical observations.
  • The presence of a DMD mutation without weakness or loss of function
  • Symptoms or signs of cardiomyopathy, including:
  • Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs
  • Echocardiogram with ejection fraction below 40%
  • Serological evidence of HIV infection, or Hepatitis A, B or C infection
  • Diagnosis of (or ongoing treatment for) an autoimmune disease
  • Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL
  • Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer
  • Subjects with rAAVrh74 binding antibody titers ≥ 1:400 as determined by ELISA immunoassay
  • Presence of circulating anti-Sda antibodies as determined by study approved laboratory.
  • Abnormal laboratory values in the clinically significant range, based upon normal values in the Nationwide Children's Hospital Laboratory

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02704325


Locations
United States, Ohio
Nationwide Children's Hospital
Columbus, Ohio, United States, 43205
Sponsors and Collaborators
Kevin Flanigan
Investigators
Principal Investigator: Kevin Flanigan, MD Nationwide Children's Hospital

Publications:
Responsible Party: Kevin Flanigan, Professor of Pediatrics, Nationwide Children's Hospital
ClinicalTrials.gov Identifier: NCT02704325     History of Changes
Other Study ID Numbers: GALGT2 for DMD
First Posted: March 10, 2016    Key Record Dates
Last Update Posted: February 6, 2018
Last Verified: February 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Kevin Flanigan, Nationwide Children's Hospital:
DMD
Duchenne Muscular Dystrophy

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked